Tildrakizumab Sustains Long-Term Efficacy for Scalp Psoriasis Treatment, reveals research
Researchers have established that tildrakizumab, an anti-interleukin-23 p19 antibody, can be used to maintain long-term efficacy and safety for moderate-to-severe scalp psoriasis. A recent study was conducted by Howard L. S. and colleagues which was published in the Journal of the American Academy of Dermatology.
Scalp psoriasis is one of the most difficult conditions to treat because of its visibility and impact on quality of life. Tildrakizumab is a targeted biologic therapy that acts on the inflammatory processes involved in this condition, and its use may offer hope for patients who do not respond to conventional therapies.
The study enrolled patients who were randomized to receive tildrakizumab (100 mg every 12 weeks) or placebo. At W16, the patients in the placebo group were switched to tildrakizumab for the rest of the trial. Efficacy endpoints were defined as achieving an IGA mod 2011; scalp score of 0 or 1 with a ≥2-grade improvement and ≥90% improvement in the PSSI 90 from baseline. The safety assessments were based on the incidence of adverse events.
Key Findings
W16 Primary Efficacy Results:
• Scalp IGA mod 2011 response rates: 49.4% for tildrakizumab compared with 7.3% for placebo.
• PSSI 90 response rates: 60.7% for tildrakizumab compared with 4.9% for placebo.
W52 Long-Term Efficacy:
• Scalp IGA mod 2011 response rates increased to 62.9% for tildrakizumab compared with 56.1% for placebo.
• PSSI 90 response rates achieved 65.2% for tildrakizumab compared with 57.3% for placebo.
Durability of Response:
• More than 80% of W16 responders to tildrakizumab were maintained at W52.
• No treatment-related serious adverse events were reported over the study period.
The study shows that in scalp psoriasis, the therapeutic efficacy of tildrakizumab has been maintained over a year of therapy. Tildrakizumab offers sustained efficacy and safety for the long-term treatment of scalp psoriasis. Therapy resulted in strong improvements in key efficacy measures, and the benefits lasted more than a year. These data position tildrakizumab as a promising option for the management of moderate-to-severe scalp psoriasis, an important area of unmet need in dermatological care.
Reference:
Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Dermatol. 2024 Dec 23:S0190-9622(24)03393-0. doi: 10.1016/j.jaad.2024.12.018
